Myocardial Expression of the Anaphylatoxin Receptor C3aR is Associated with Cardiac Inflammation and Prognosis in Patients with Non-Ischaemic Heart Failure
Open Access
- 31 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 5 (5) , 846-857
Abstract
Aim The aim of this study is to analyse the prognostic value of complement anaphylatoxin receptors in patients with non‐ischaemic cardiomyopathy undergoing endomyocardial biopsy. Methods and results In 102 patients (72.5% male patients, median age 54 years) with non‐ischaemic cardiomyopathy, myocardial expression of C3aR was assessed among other parameters. The primary study endpoint was a composite of death, heart transplantation, heart failure‐related re‐hospitalization, and deterioration of left ventricular ejection fraction within a mean follow‐up of 11.9 months. The number of cells, which stained positive for C3aR, was significantly increased in patients with inflammatory compared with non‐inflammatory cardiomyopathy (1.75 ± 0.31 cells in inflammatory cardiomyopathy vs. 0.94 ± 0.26 in non‐inflammatory cardiomyopathy, P = 0.049). Subsequently, positive expression for C3aR was judged based on a semi‐quantitative scoring system. Significantly, more patients with positive MHCII and CD68 expression showed an increased number of C3aR‐positive cells. C3aR expression based on this score was more pronounced in patients with human herpesvirus 6 viral genome detection. Kaplan–Meier curves illustrate that the C3aR‐negative group reached the primary endpoint significantly more often (mean follow‐up 11.9 months, log rank 5.963, P = 0.015). Lack of C3aR expression was a strong independent predictor for the primary endpoint in Cox regression analysis [hazard ratio 0.46 (0.26–0.82, P = 0.009)]. Conclusions C3aR‐positive cells are found more often in patients with inflammatory cardiomyopathy. The relevance of C3aR‐positive cells in patients with non‐ischaemic cardiomyopathy should be further evaluated as potential predictors or modulators of adverse cardiac remodelling, the substrate of progressive heart failure.Keywords
Funding Information
- TÜFF Frauenförderungsprogramm of the University Tübingen (2241-0-0)
- Deutsche Forschungsgemeinschaft (KFO 274)
- Volkswagen Foundation (Lichtenberg program)
- Deutsche Forschungsgemeinschaft (KFO 274)
- Volkswagen Foundation (Lichtenberg program)
This publication has 43 references indexed in Scilit:
- Prognostic Value of Contrast-enhanced Cardiac Magnetic Resonance Imaging in Patients with Newly Diagnosed Non-Ischemic Cardiomyopathy: Cohort StudyPLOS ONE, 2013
- Regulation of the Inflammatory Response in Cardiac RepairCirculation Research, 2012
- Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8–mediated activation of TGF-βJournal of Clinical Investigation, 2011
- Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection FractionCirculation: Heart Failure, 2011
- Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesisBlood, 2010
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Functions of C5a receptorsJournal of Molecular Medicine, 2009
- Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseasesEuropean Heart Journal, 2007
- The role of intravenous immunoglobulin in the treatment of chronic heart failureInternational Journal of Cardiology, 2006
- Myocardial proteases and matrix remodeling in inflammatory heart diseaseCardiovascular Research, 2006